Nintedanib medical insurance reimbursement process and patient application guide

Nintedanib is a multi-target tyrosine kinase inhibitor mainly used to treat idiopathic pulmonary fibrosis (IPF), systemic sclerosis-related interstitial lung disease (SSc-ILD) and certain non-small cell lung cancers. The drug has been officially launched in China and has been included in the National Medical Insurance List. Despite this, the pre-medical insurance price of nintedanib is still high. Generally, the price of a box may be around several thousand yuan. Therefore, medical insurance coverage is crucial for patients, effectively reducing the financial pressure of long-term treatment.

If a patient needs to be reimbursed for nintedanib through medical insurance, he or she must first go to a hospital designated by the medical insurance and have a prescription issued by a specialist with prescription authority (usually a respiratory or oncologist). Subsequently, patients should bring their medical insurance card, ID card, outpatient medical records or hospitalization information to the hospital pharmacy or medical insurance office to complete the drug purchase and reimbursement registration procedures. Some regions support "purchase drugs first and reimburse later", while most provinces and cities have opened "real-time settlement", that is, medical insurance directly reimburses part of the cost, and patients only need to pay the out-of-pocket portion.

There are slight differences in medical insurance policies in different regions. The reimbursement ratio of nintedanib in each region, whether it is included in "dual-channel" management, and whether it needs to go through the chronic and special disease reimbursement channel, all need to be based on the policies of the local medical insurance bureau or the hospital's medical insurance department. In some areas, patients with idiopathic pulmonary fibrosis need to undergo "chronic disease registration" or "special disease approval" in order to enjoy a higher reimbursement rate. It is recommended that patients go to the hospital's medical insurance office to consult the relevant procedures before prescribing medicine for the first time to avoid incomplete processes or blocked reimbursement.

Although the country has been included in the medical insurance system, the price is still a big burden for some patients with low reimbursement ratios or those who are not eligible for medical insurance. At present, India and other countries have launched generic drugs of nintedanib. The price is about RMB 400 to 500 per box, which is much lower than the cost of domestic original drugs. Most of these generic drugs are produced by well-known Indian pharmaceutical companies, such as Cipla or Natco, and their active ingredients are basically the same. If patients consider purchasing drugs overseas, they must ensure the quality and safety of the drugs through formal channels, platforms or cross-border medical institutions, and take them under the guidance of professional doctors.

Reference materials:https://www.drugs.com/